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soft tissues, brain gliomas expand by creating new space as a result of tissue destruction. They accomplish this task by releasing glutamate, which kills surrounding neurons via an excitotoxic mechanism. Accordingly, glioma cell lines that lack glutamate transporters at the cell surface expand more rapidly as a result of glutamate accumulation in the extracellular space (Takano et al., 2001) . Interestingly, glioma cells express ionotropic glutamate receptors, which respond to extracellular glutamate promoting tumor growth and/or migration (Ishiuchi et al., 2002; Rzeski et al., 2001 ). We and others have found that glioma cells also express metabotropic glutamate (mGlu) 5 receptors (Aronica et al., 2003; Condorelli et al., 1997; D'Onofrio et al., 2003) . These receptors form a family of eight subtypes, of which mGlu1 and mGlu5 are coupled to Gq proteins, whereas all other subtypes (mGlu2, mGlu3, mGlu4, mGlu6, mGlu7, and mGlu8) are coupled to Gi proteins in recombinant cells . The mGlu3 receptors are consistently found in primary cultures obtained from human glioblastomas, as well as in a number of glioma cell lines. The mGlu2 and mGlu5 receptors are found only occasionally in glioma cells (Condorelli et al., 1997; D'Onofrio et al., 2003) . Pharmacological blockade of mGlu2/3 receptors produces antiproliferative effects in cultured glioma cells and reduces the activation of the MAP kinase (MAPK) pathway induced by epidermal growth factor (EGF) or other mitogens . This is particularly interesting from a therapeutic standpoint because ligands of mGlu2 and mGlu3 receptors represent an expanding class of drugs endowed with a high receptor affi nity, brain penetration, and a good profi le of safety and tolerability Schoepp et al., 1999) . However, the effi cacy of mGlu2/3 receptor antagonists cannot be easily predicted from in vitro data because these drugs in vivo might produce effects that are detrimental to the fi nal outcome of malignant gliomas, such as a facilitation of excitotoxic neuronal death (Battaglia et al., 1998; Bruno et al., 2001; Kingston et al., 1999; Poli et al., 2003) or a reduced expression of the excitatory amino acid carrier 1 glutamate transporter (Aronica et al., 2003) . In addition, it is not known whether glioma cells proliferating in their native environment (i.e., inside the brain) still express mGlu2/3 receptors and retain the sensitivity to mGlu2/3 receptor antagonists. Here we show that a chronic treatment with the potent and brain-permeant mGlu2/3 receptor antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) (Kingston et al., 1998) reduces the growth of glioma cells implanted either under the skin or inside the brain of mice.
Methods

Materials
LY341495, (2S)-␣-ethylglutamate (EGlu), and (RS)-␣-methyl-4-tetrazolylphenylglycine (MTPG) were obtained from Tocris Cookson Ltd. (Bristol, UK). The (-)-2-oxa-4-aminobicyclo [3, 1, 0] hexane-4,6-dicarboxylic acid (LY379268) was a gift. All other chemicals were purchased from Sigma (Milan, Italy).
Cell Cultures
U87MG human glioblastoma continuous cell lines were obtained from the American Type Culture Collection (Manas sas, Va.). Cells were grown in Dulbecco's Modifi ed Eagle's Medium supplemented with 10% fetal calf serum (Life Technologies Ltd., Milan, Italy) and were plated in Falcon Primaria culture dishes (Becton Dickinson, Lincoln Park, N.J.). The medium was changed every three days. After 14 to 15 days, cells were trypsinized and replated into 24-well plates at a density of 25 ϫ 10 3 cells per well and shifted into Dulbecco's Modifi ed Eagle's Medium Glutamax without serum (Life Technologies Ltd.). Glutamax was used instead of glutamine, which is a potential chemical source of glutamate.
Cell Cycle Analysis
Fluorescence-activated cell sorting (FACS) analysis of cell cycle and DNA ploidy was carried out with a Coulter Elite fl ow cytometer (Beckman Coulter, Milan, Italy) after staining with propidium iodide (50 g/ml) and treatment for 1 h with RNAse (100 g/ml, as described previously [Copani et al., 1999] ).
RNA Isolation and RT-PCR Analysis
Two micrograms of total RNA extracted from glioma cultures (Ultraspec, Biotech, Houston, Tex.) and 100 ng of random hexamers dissolved in 12 l of RNAse-free water were heated at 65°C for 15 min and then cooled on ice for 1 min. Five microliters of Moloney murine leukemia virus buffer 5ϫ, deoxynucleotide-5'-triphosphate (500 nM) and dithiotreitol (10 nM), then 1 l of Moloney murine leukemia virus (200 U), were added (Life Technologies Ltd.), and the mix was incubated for 60 min at 42°C. Polymerase chain reaction analysis was carried out in 50 l of a Tris-HCl (10 mM, pH 8.8) buffer containing MgCl 2 (1.5 mM); Triton X-100 (0.1%); deoxythymidine-5'-triphosphate, deoxyguanosine-5'-triphosphate, deoxycytidine-5'-triphosphate, and deoxyadenosine-5'-triphosphate (200 M each); forward and reverse primers (25 pmol each); and 10 l of single-stranded cDNA. Taq polymerase (1 U) (Promega, Milan, Italy) was added in hot-start conditions (95°C for 3-5 min), and 35 cycles were carried out as follows: 95°C for 1 min, 58°C for 1 min, and 72°C for 1 min. Amplifi cation products were separated by agarose gel (2%) and stained with ethidium bromide. Primers used were as follows. Cultures were starved in serum-free medium for 72 h and then stimulated with EGF (100 ng/ml) plus LY341495 (1 M) and/or LY379268 (1 M) for 10 min for the detection of phosphorylated extracellular signal-regulated kinase 1 (ERK1)//ERK2 or phosphorylated Akt, and for 8 h for the detection of cyclin D1/2. We used phospho-ERK1/ERK2 (1:2000) and nonphosphorylated ERK1/ ERK2 (1:1000) monoclonal antibodies (New England Biolabs, Beverly, Mass.), phospho-Akt (1:1000) and nonphosphorylated Akt (1:1000) polyclonal antibodies (Cell Signaling Technology, Beverly, Mass.), and polyclonal antibodies raised against synthetic peptides corresponding to the 11 C-terminal amino acids of human cyclin D1, which cross-reacts with cyclin D2 (1.5 g/ml, Santa Cruz, Calif.). Western blot analysis was carried out as described above.
Determination of Extracellular L-Glutamate Levels
Analysis of glutamate in the medium of cultured U87MG cells was performed by precolumn derivatization with o-phthalaldehyde and mercaptoethanol, followed by high-performance liquid chromatography with fl uorescence detection, as described previously .
U87MG Cell Implantation
Male CD1 nude mice (20-22-g body weight; Charles River, Calco, CO, Italy) were kept under controlled conditions (temperature, 22°C; humidity, 40%) on a 12-h light/dark cycle with food and water ad libitum. Experiments were performed following the guidelines for animal care and use promulgated by the National Institutes of Health (Bethesda, Md.). Mice were subcutaneously implanted with 1 ϫ 10 6 U87MG cells/0.5 ml. Mice were implanted at the same time with osmotic minipumps releasing 250 nl/h for 28 days (Alzet, Cupertino, Calif.) filled with saline, LY341495, or EGlu. Implantation was performed on mice under ketamine (100 mg/kg, i.p.)/xylazine (10 mg/kg, i.p.) anesthesia. The weight of subcutaneous tumors was assessed after one month. In another set of experiments, U87MG cells were stereotaxically implanted into the left caudate nucleus (by using the following coordinates: 0.6 mm anterior to the bregma; 1.7 mm lateral to the midline; and 4.5 mm ventral from the surface of skull [Franklin and Paxinos, 1997] ) of mice under ketamine (100 mg/kg, i.p.)/xylazine (10 mg/kg, i.p.) anesthesia. Cells (0.5 ϫ 10 6 cells/5 l) were implanted at an infusion rate of 1 l/min. The needle was left in place 5 min after cell infusion before it was withdrawn. Mice were chronically treated with saline or LY341495 by means of small osmotic minipumps (Alzet) releasing 500 nl/h for 7 days. Minipumps were removed just prior to each session of MRI analysis and then substituted after the analysis while the animals were under isofl urane anesthesia, as described below.
MRI Analysis
MRI analysis was carried out at 4.7 tesla (T) by using a Varian Inova SIS 200/183 system (Varian, Palo Alto, Calif.) equipped with a 4.0-cm-diameter, circularly polarized coil. T1-weighted multislice spin-echo scout images (xz, xy) were obtained with TR/TE ϭ 500/16 ms, NS ϭ 4, slice thickness of 1.0 mm, and matrix 128 ϫ 512. T2-weighted (x,y) images were acquired only on the fi rst day of analysis: TR/TE ϭ 2500/70 ms, NS ϭ 4, slice thickness of 1.0 mm, and matrix 128 ϫ 512. The total volume of each tumor was measured by using a series of axial, post-gadolinium-enhanced diethylenetriamine pentaacetic acid (3.0 ml/kg, s.c.), T1-weighted, spin-echo sequence images. Tumor volume was evaluated by using a dedicated image browser program (Varian); the area of the lesion was indicated manually, and the mean value from the evaluations was calculated by two independent investigators. The area of interest was manually defi ned on each single slice and the total volume automatically measured; two separate measures were performed by two independent blind investigators. Animals were anesthetized with 1% isofl urane in O 2 (1 liter/min), and body temperature was maintained constant by means of a water bed at 37°C. The presence of a brain tumor was demonstrated in 49 of 55 mice injected in the striatum with U87MG cells. Mice were subjected to MRI analysis every seven days after cell implantation.
Immunohistochemistry and Histological Analysis
Brains were fi xed in 4% formaldehyde in 0.1 M phosphate buffer (pH 7.2). Serial sections were stained with hematoxylin and eosin. Immunohistochemistry for the proliferation marker, Ki-67 (Ventana, Tucson, Ariz.), and for the mGlu2/3 receptor (1:100) (Chemicon) was performed automatically with a Nexes instrument (Ventana). Antibody detection was performed by using a multilink streptavidin-biotin complex method, and antibodies were visualized by a diaminobenzidine chromagen method. Negative control samples were incubated with primary antibodies only. The number of Ki-67-positive cells was determined in four random fi elds (1 cm 2 each) by using the ImageJ 1.31v software (National Institutes of Health).
Results
We previously observed that glioma cells in culture respond to the mGlu2/3 receptor antagonist LY341495 with a reduced proliferation rate . However, our initial attempts to implant nude mice with cells isolated from surgically removed human gliomas failed because of the limited growth rate of these cells. We therefore used U87MG glioma cells for in vivo studies. These cells expressed both mGlu2 and mGlu3 receptor mRNA (Fig. 1A) , as well as the mGlu2/3 recep- tor protein (Fig. 1B) . We did not detect any expression of mGlu1, mGlu4, mGlu5, or mGlu7 mRNA (Fig. 1A) or mGlu5 receptor protein (not shown). A daily addition of LY341495 (1 M), MTPG (100 M), or EGlu (100 M) to cultured U87MG cells reduced cell proliferation in a time-dependent manner. In cultures treated with LY341495 or MTPG, a reduction in cell proliferation was seen after three and four days (particularly between the second and third day of exposure (Fig. 1C) . EGlu was less effective than the other two antagonists and reduced cell proliferation only after four days of exposure (Fig. 1C) . FACS analysis of cell cycle in cells treated with LY341495 for two days showed a signifi cant reduction in the percentage of cells in the S and G 2 M phases of the cell cycle that was associated with an increased percentage of cells in the G 0 /G 1 phase. The distribution of the cell cycle phases in cells treated with LY341495 for four days did not differ from the distribution in control cells (Table 1) . LY341495 treatment did not induce apoptosis of U87MG cells, as assessed by FACS analysis of prediploid DNA (not shown). LY341495 (1 M) reduced the activation of the MAPK pathway (as assessed by Western blot analysis of phosphorylated ERK1/ERK2), the activation of the PI-3-K pathway (as assessed by Western blot analysis of phosphorylated Akt), and the expression of cyclin D1/2 induced by the mitogen EGF (100 ng/ml) in cultured U87MG cells deprived of serum for 72 h. All of these effects were reversed by the coapplication of the potent mGlu2/3 receptor agonist, LY379268, which was inactive per se (Figs. 1D-F) . In cells deprived of serum for 72 h, extracellular glutamate concentrations were 92 Ϯ 21 M (n ϭ 5). Cultures treated with LY341495 were also used to assess whether antagonist treatment could induce adaptive changes in the expression of mGlu2/3 receptors. Western blot analysis showed that exposure to LY341495 did not change mGlu2/3 levels (at least up to four days of treatment) (Fig. 2) .
To examine whether pharmacological blockade of mGlu2/3 receptors could reduce glioma cell growth in vivo, we fi rst implanted U87MG under the skin of nude mice (1 ϫ 10 6 /0.5 ml). At the same time, mice were subcutaneously implanted with osmotic minipumps releasing saline, LY341495 (1 mg/kg per day), EGlu (1 mg/kg per day), LY379268 (1 mg/kg per day), or LY341495 + LY379268 for 28 days. Analysis of tumor weight after one month showed that chronic infusion with mGlu2/3 receptor antagonists LY341495 or EGlu reduced glioma cell growth (Figs. 3A, B) . Infusion with the receptor agonist LY379268 did not affect tumor growth and failed to reverse the lowering effect of LY341495, although the weight of tumors in mice treated with LY341495 + LY379268 tended to be higher than that in mice treated with LY341495 alone (Fig. 3B) .
In another series of experiments, we implanted U87MG cells into the left caudate nucleus of nude mice (0.5 ϫ 10 6 cells/5 l for 5 min). Mice were subjected to MRI analysis every seven days after cell implantation. T2-weighted images were acquired only after the fi rst seven days and did not show the presence of edema at the injection site of U87MG cells. Contrast-enhanced T1-weighted images showed the presence of a tumor, which grew progressively from day 7 to day 28 following cell implantation (Fig. 4A) . In most of the animals, the exponential phase of tumor growth was observed between 21 and 28 days after cell implantation. Histological examination of xenografts carried out after the last MRI analysis at 28 days showed a homogenous tumor mass with sharp borders, which was clearly delimited from the adjacent brain tissue. Cytologically, tumors were composed of large pleomorphic cells with abundant eosinophilic cytoplasms (Figs. 4B, C) . Most glioma cells were immunopositive for mGlu2/3 receptors (Figs. 4D, E) , as well as for the proliferation marker, Ki-67. After the fi rst MRI analysis at seven days, selected mice with similar tumor sizes were subdivided into two groups and subcutaneously implanted with osmotic minipumps releasing either saline or LY341495 (10 mg/ kg per day) subcutaneously for seven days. Minipumps were removed just prior to the next MRI analysis (for technical reasons) and replaced afterward.
Results of two independent experiments are shown in Figs. 5C and 5D. Treatment with LY341495 reduced the growth rate of brain tumors in both experiments. The action of the drug was particularly evident between day 21 and day 28 following cell implantation, that is, during the exponential phase of growth. In the second experiment, four mice were withdrawn from LY341495 on day 21. In these mice, tumor volume increased to the same extent as in control mice from day 21 to day 28, which indicated that the effect of LY341495 was reversible (Fig.  5D ). Mice were not allowed to survive beyond 28 days after cell implantation to avoid the occurrence of severe neurologic symptoms. Only fi ve mice died during the 28 days of the experiments. All of these mice were from the control groups treated with saline. Histological analysis did not show any difference between the morphology of tumor cells of mice treated with saline and that of mice treated with LY341495. No detectable edema was found around or inside the tumor specimens from control and LY341495-treated mice. Treatment with LY341495 signifi cantly reduced the number of Ki-67-positive cells in tumor specimens (Fig. 6 ).
Discussion
There have been few signifi cant advances in the treatment of malignant gliomas over the last two decades. Compared with other brain tumors (e.g., primary CNS lymphomas, anaplastic oligodendrogliomas, and pediatric embryonal tumors), tumors of the astrocytic lineage show a poor responsiveness to cytotoxic chemotherapy because of the development of chemoresistance (Bredel and Zentner, 2002) . This encourages the search for alternative drug treatments aimed at improving the prognosis of malignant gliomas. Recent evidence suggests that gliomas may be "perverting glutamate and ion homeostasis" to support their unusual growth and invasive migration (Sontheimer, 2003) . Glioma cell growth inside the brain is favored by an active release of glutamate combined with a low expression of sodium-dependent membrane glutamate transporters (Takano et al., 2001; . This leads to excitotoxic death of surrounding neurons, a process that creates the necessary space for tumor expansion . Drugs that protect neurons against excitotoxic death (e.g., N-methyl-d-aspartate receptor antagonists) or inhibit the glutamate/cystine membrane exchanger (i.e., the main system accounting for the release of glutamate) are potential candidates for the treatment of malignant gliomas. Inhibitors of the glutamate/cystine cotransporter will also limit the intracellular synthesis of glutathione, a molecule involved in mechanisms of chemoresistance (Reichelt et al., 1997) . Interestingly, glioma cells express amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors lacking the GluR2 subunit, which acts as a negative dominant in controlling the Ca 2+ permeability of AMPA-gated ion channels (Burnashev et al., 1992; Sommer et al., 1991) . Activation of AMPA receptors in glioma cells generates Ca 2+ transients that support cell migration and survival, thus facilitating tumor expansion (Ishiuchi et al., 2002) .
Using glioma cultures from bioptic human samples or glioma cell lines, we have shown that pharmacological blockade of mGlu3 metabotropic glutamate receptors reduces cell proliferation and MAPK activation. This effect was seen in all selected glioma cell cultures expressing mGlu3 receptors . Here, we have shown that a continuous systemic infusion of the potent mGlu2/3 receptor antagonist LY341495 Kingston et al., 1998) reduced the growth of glioma cells implanted either under the skin or inside the brain of recipient mice. These two models are complementary because the growth of cells implanted in a soft tissue (i.e., subcutaneously) relies exclusively on the rate of proliferation and on an adequate energy supply, whereas the growth of a brain glioma is the result of multiple processes such as the excitotoxic death of surrounding neurons, the expression of enzymes that degrade the extracellular matrix, and the expression of ion channels that drive the movement of water out of the cell (Bowman et al., 1999) . However, one must consider that glioma cells implanted in the mouse brain tend to grow uniformly, with the resulting brain tumor appearing as a homogenous mass at MRI and histological analysis. This contrasts with primitive advanced-stage gliomas, which disseminate asymmetrically, with cells migrating along blood vessels and fi ber tracts (Giese, 2003) . Thus, in our model, the contribution of cell shrinkage to the overall tumor growth is minimized.
We used a cell line (U87MG) for in vivo studies because cells from surgically removed human gliomas (that we had used in vitro) showed a limited growth when implanted either subcutaneously or inside the brain of nude mice. U87MG cells expressed both mGlu2 and mGlu3 receptors, two highly homologous receptors that share the same pharmacological profi le (Sallese et al., 2001 ), but not other mGlu receptor subtypes. This is noteworthy because the antagonist LY341495 binds with nanomolar affi nity to mGlu2 and -3 receptors, but it recruits additional mGlu receptor subtypes at higher concentrations . Because of its very high affi nity, LY341495 can antagonize the activation of mGlu2/3 receptors by micromolar concentrations of ambient glutamate (the affi nity of glutamate for mGlu2 and mGlu3 receptors is usually in the range of 2 to 10 M ). U87MG cells in vitro responded to a single pulse of LY341495 with a reduced activation of the MAPK and PI-3-K pathways (which are both implicated in glioma cell proliferation) and a reduced expression of cyclin D1 (an early marker of the G 1 /S phase transition) in response to the mitogen EGF. All of these effects were reversed by the combined application of LY379268, a potent subtype-selective agonist with a nanomolar affi nity for mGlu2 and mGlu3 receptors (reviewed by Schoepp et al. [1999] ), suggesting that endogenous activation of mGlu2/3 receptors supports proliferation of U87MG cells. This was confi rmed by experiments in which U87MG cells were continuously exposed to mGlu2/3 receptor blockers up to four days. Inhibition of cell growth was seen after exposure to LY341495, MTPG, and EGlu, three drugs that share the ability to antagonize both mGlu2 and mGlu3 receptors (see Shoepp et al. [1999] ). In cultured U87MG cells treated with LY341495 in particular, cell growth was substantially reduced between the second and the third day of drug exposure and recovered afterward. This is different from what has been observed in primary cultures of human brain gliomas, in which the inhibitory action of LY341495 on cell growth was fully maintained after four days of exposure . The transient nature of the effect of LY341495 on U87MG cell growth was confi rmed by FACS analysis of the cell cycle, which showed the ability of the drug to reduce the percentage of cells in the S and G 2 M phases of the cell cycle after two days but not after four days of exposure. Whether this refl ects the development of mGlu2 or mGlu3 receptor supersensitivity in response to the long-term receptor blockade in vitro is unknown because information on the adaptive changes in the activity of these receptors upon continuous drug exposure is lacking. However, it is noteworthy that no changes in the expression of mGlu2/3 receptors (detected by Western blot analysis) were found in cultured U87MG cells exposed to LY341495 up to four days. Thus, the mechanisms underlying the transient effect of mGlu2/3 receptor blockade on the proliferation rate of U87MG cells in culture remain obscure.
When cells were implanted subcutaneously, LY341495 reduced tumor growth even in the presence of equimolar doses of LY379268. The incomplete knowledge available on the pharmacokinetics of mGlu receptor ligands would prohibit accurate pharmacological experiments that might disclose an interaction between LY341495 and LY379268 in vivo. However, a critical role for mGlu2/3 receptors is suggested by the reduced tumor growth observed in mice treated with EGlu, which selectively antagonizes mGlu2/3 receptors (Jane et al., 1996) . The fi nding that systemic infusion of LY341495, a drug that can cross the blood-brain barrier , limits tumor growth inside the mouse brain is particularly encouraging from a therapeutic standpoint and suggests that inhibition of cell proliferation overcomes any possible detrimental effect of the drug on tumor growth, such as the facilitation of excitotoxic neuronal death (Battaglia et al., 1998; Poli et al., 2003) . We have no information on the fi nal outcome of brain tumors in mice treated with LY341495 because animals were not allowed to survive beyond the fourth week of tumor growth. However, it is noteworthy that none of the fi ve mice that died during the four weeks of observation belonged to the groups treated with LY341495. We expect that treatment with systemically active mGlu2/3 receptor antagonists will be even more effective in reducing the growth of primary brain gliomas, because the antiproliferative action of LY341495 was persistent in primary cultures of human gliomas (whereas it was transient in cultured U87MG cells). We did not test this directly because the growth of glioma cells isolated from human brain tumors was very slow in the brain of recipient nude mice. Other questions that need to be addressed are whether LY341495 synergizes with classical cytotoxic agents used in clinical practice and whether mGlu2/3 receptors present in glioma cells control the expression of proteins or enzymes involved in mechanisms of chemoresistance.
